Brief: AIM Immunotech reports Q2 results
15/08/2022 13:08
Aug 15 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
* AIM IMMUNOTECH INC - CAPITAL POSITION EXPECTED TO FUND
COMPANY
THROUGH END OF 2023
* AIM IMMUNOTECH INC - QTRLY LOSS PER SHARE $0.10
Source text for Eikon: ID:nGNX833cjT
Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential